Forest's preservative free heparin
Executive Summary
FDA is asking the firm to recall all stocks of the drug remaining in retail channels because of potential safety concerns. The agency noted in a Sept. 11 reg letter that there is a "lack of assurance of sterility for lots of preservative-free sodium heparin injection currently in distribution." Forest said it discontinued marketing the DESI product after recall of one lot of the product in February due to contamination ("The Pink Sheet" March 17, T&G-7).
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.